US2021002256A1PendingUtilityA1
Tlr7/8 antagonists and uses thereof
Est. expiryAug 8, 2036(~10 yrs left)· nominal 20-yr term from priority
A61K 31/4375C07D 471/10C07D 413/14C07D 413/04C07D 401/14C07D 241/42C07D 215/18C07D 215/14C07D 215/12C07D 401/12C07D 487/04C07D 401/04C07D 471/08C07D 471/04C07D 451/02C07D 487/08A61P 29/02A61P 29/00A61P 25/28A61P 25/16A61P 19/10A61P 19/08A61P 19/06A61P 19/02A61P 17/06A61P 17/00A61P 13/12A61P 9/10A61P 3/10A61P 1/04A61K 31/5377A61K 31/4995A61K 31/498A61K 31/4709A61K 31/4545A61P 25/00A61K 31/496A61P 35/00A61P 43/00A61P 37/02A61P 31/04C07D 215/04
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
or pharmaceutically acceptable compositions thereof, is useful to as a TLR7/8 antagonist.
Claims
exact text as granted — not AI-modified1 . A compound of formula I,
Ring A is aryl or heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
Ring B is heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
R 1 is —H, —CH 3 —, —CF 3 —, —CN, —F, —Cl, —OCH 3 , or —OCF 3 ;
each R 2 is independently —H, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO 2 , —SO 2 R, —SOR, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, or —N(R) 2 ;
each R 3 is independently —H, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO 2 , —SO 2 R, —SOR, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, or —N(R) 2 ;
X is C(R 4 ) 2 ;
Y is C(R) 2 ;
each R 4 is independently —H, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO 2 , —SO 2 R, —SOR, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —C(NH)R, —C(NH)NR 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, or —N(R) 2 ;
each R 5 is independently —H, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO 2 , —SO R, —SOR, —C(O)R, —CO 2 R, —C(O)N(R) 2 , —NRC(O)R, —NRC(O)N(R) 2 , —NRSO 2 R, or —N(R) 2 ;
each R is independently hydrogen, C 1-6 aliphatic, C 3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
two R groups on the same atom are taken together with the atom to which they are attached to form a C 3-10 aryl a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
k is 1 or 2;
n is 0, 1, or 2;
p is 0, 1, or 2;
r is 0, 1, or 2; and
t is 0, 1, or 2.
2 . The compound of claim 1 , wherein Ring A is C 6 aryl or a 6 membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
3 . The compound of claim 2 , wherein Ring A is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl.
4 . The compound of claim 3 , wherein Ring A is
5 . The compound of claim 1 , wherein Ring B is a 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
6 . The compound of claim 5 , wherein Ring B is
7 - 8 . (canceled)
9 . The compound of claim 1 , wherein each R 4 is independently C 1-6 aliphatic, —C(O)R, —C(NH)NR 2 , —NRC(O)R, —N(R) 2 ; or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted.
10 . The compound of claim 9 , wherein each R 4 is independently
11 . The compound of claim 1 , wherein each R 5 is independently C 1-6 aliphatic, C 3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted.
12 . The compound of claim 11 , wherein each R 5 is independently methyl, ethyl, ethyl, propyl, i-propyl, butyl, s-butyl, t-butyl, straight or branched pentyl, or straight or branched hexyl; each of which is optionally substituted.
13 . The compound of claim 1 , of formula I-a,
or a pharmaceutically acceptable salt thereof.
14 . The compound of claim 1 , of formula I-b,
or a pharmaceutically acceptable salt thereof.
15 . The compound of claim 1 , selected from the group consisting of compounds shown in the following Table
Compound 120
Compound 121
Compound 122
Compound 123
Compound 124
Compound 125
Compound 126
Compound 127
Compound 128
Compound 129
Compound 130
Compound 131
Compound 132
Compound 133
Compound 134
Compound 135
Compound 136
Compound 137
Compound 138
Compound 139
Compound 140
Compound 141
Compound 142
Compound 143
Compound 144
Compound 145
Compound 146
Compound 147
Compound 148
Compound 149
Compound 150
Compound 151
Compound 152
Compound 153
Compound 154
Compound 155
Compound 156
Compound 157
Compound 158
Compound 159
Compound 160
16 . A pharmaceutical composition, comprising:
the compound of claim 1 , and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
17 . A method for inhibiting TLR7/8, or a mutant thereof, activity in a patient or in a biological sample, comprising:
administering to said patient or contacting said biological sample with the compound of claim 1 or a physiologically acceptable salt thereof.
18 . A method for treating a TLR7/8-mediated disorder in a patient in need thereof, comprising:
administering to said patient the compound of claim 1 or a physiologically acceptable salt thereof.
19 . The method of claim 18 , wherein the disorder is selected from Rheumatoid Arthritis, Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, Sjoren's disease, polymyositis, dermatomyositis, and Cancer.
20 . A method for treating cancer in a subject, comprising:
administering to said subject the compound of claim 1 or a physiologically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2021002256A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.